Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Phase 1b/2a results (published in The Lancet, 2025): - In 125 adults with overweight or obesity, the subcutaneous 20 mg dose achieved 22.0% absolute weight loss (23.9% placebo-adjusted)
Tests To Monitor GLP-1 To Control Blood Sugar Regular medical monitoring is crucial to ensure both the safety and effectiveness of treatment
Semaglutide Has an FDA Indication for MASH Wegovy received FDA accelerated approval for MASH (metabolic dysfunction-associated steatohepatitis) in August 2025
The MIC compounds work to break down fat in the liver, promoting fat metabolism and assisting in weight loss
Yes, it's safe during pregnancy at recommended doses
The reconstituted form requires stricter temperature control, more careful handling, and has a significantly shorter usable lifespan
US$ 21.60
US$ 24.43
US$ 27.32
US$ 28.15
